Therapeutic Approaches Targeting Prostate Cancer Progression Using Novel Voltage-Gated Ion Channel Blockers

Robert A. Sikes, Alison M. Walls, William Brennen, James D. Anderson, Indrani Choudhury-Mukherjee, Hilary A. Schenck, Milton L. Brown

Research output: Contribution to journalArticle

Abstract

The early detection and treatment of prostate cancer have increased survival and improved clinical outcomes. The nature of the disease and pathologic understaging result in a high proportion of patients developing locally recurrent disease or distant metastases. The development of prostate cancer-the time from tumor initiation and progression to invasive carcinoma-often begins in men in the fourth or fifth decades of life and extends across decades. This prolonged window highlights the tremendous clinical impact that early intervention with therapeutic agents that selectively target the invasive and metastatic potential of the prostate cancer cell could have on patient survival and quality of life. Our research is currently focused on the development and testing of novel voltage-gated ion channel blockers. The expression of voltage-gated sodium channels (VGSCs) was recently associated with the metastatic behavior of prostate cancer cells. In these studies, VGSC blockers altered prostate cancer cell morphology and arrested prostate cancer cell migration. Clinically, one of the most widely used sodium channel blockers is phenytoin. We have used rational drug design based on the phenytoin binding site in a VGSC to make novel sodium channel blockers with enhanced activity and minimal acute toxicity. Our initial studies in vitro demonstrate enhanced binding of the compounds to the sodium channel and increased inhibition of prostate cancer cell growth in culture and in soft agarose compared with phenytoin. These derivatives are currently being tested for their antitumor activity in human prostate cancer xenografts.

Original languageEnglish (US)
Pages (from-to)181-187
Number of pages7
JournalClinical Prostate Cancer
Volume2
Issue number3
StatePublished - Dec 2003
Externally publishedYes

Fingerprint

Ion Channels
Prostatic Neoplasms
Phenytoin
Sodium Channel Blockers
Voltage-Gated Sodium Channels
Therapeutics
Voltage-Gated Sodium Channel Blockers
Survival
Sodium Channels
Drug Design
Heterografts
Human Activities
Sepharose
Cell Movement
Binding Sites
Quality of Life
Neoplasm Metastasis
Carcinoma
Growth
Research

Keywords

  • Calcium ions
  • Invasive disease
  • Proliferation
  • Sodium channel blockade

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Sikes, R. A., Walls, A. M., Brennen, W., Anderson, J. D., Choudhury-Mukherjee, I., Schenck, H. A., & Brown, M. L. (2003). Therapeutic Approaches Targeting Prostate Cancer Progression Using Novel Voltage-Gated Ion Channel Blockers. Clinical Prostate Cancer, 2(3), 181-187.

Therapeutic Approaches Targeting Prostate Cancer Progression Using Novel Voltage-Gated Ion Channel Blockers. / Sikes, Robert A.; Walls, Alison M.; Brennen, William; Anderson, James D.; Choudhury-Mukherjee, Indrani; Schenck, Hilary A.; Brown, Milton L.

In: Clinical Prostate Cancer, Vol. 2, No. 3, 12.2003, p. 181-187.

Research output: Contribution to journalArticle

Sikes, RA, Walls, AM, Brennen, W, Anderson, JD, Choudhury-Mukherjee, I, Schenck, HA & Brown, ML 2003, 'Therapeutic Approaches Targeting Prostate Cancer Progression Using Novel Voltage-Gated Ion Channel Blockers', Clinical Prostate Cancer, vol. 2, no. 3, pp. 181-187.
Sikes RA, Walls AM, Brennen W, Anderson JD, Choudhury-Mukherjee I, Schenck HA et al. Therapeutic Approaches Targeting Prostate Cancer Progression Using Novel Voltage-Gated Ion Channel Blockers. Clinical Prostate Cancer. 2003 Dec;2(3):181-187.
Sikes, Robert A. ; Walls, Alison M. ; Brennen, William ; Anderson, James D. ; Choudhury-Mukherjee, Indrani ; Schenck, Hilary A. ; Brown, Milton L. / Therapeutic Approaches Targeting Prostate Cancer Progression Using Novel Voltage-Gated Ion Channel Blockers. In: Clinical Prostate Cancer. 2003 ; Vol. 2, No. 3. pp. 181-187.
@article{80b63089c87948b691d1a873a67dde27,
title = "Therapeutic Approaches Targeting Prostate Cancer Progression Using Novel Voltage-Gated Ion Channel Blockers",
abstract = "The early detection and treatment of prostate cancer have increased survival and improved clinical outcomes. The nature of the disease and pathologic understaging result in a high proportion of patients developing locally recurrent disease or distant metastases. The development of prostate cancer-the time from tumor initiation and progression to invasive carcinoma-often begins in men in the fourth or fifth decades of life and extends across decades. This prolonged window highlights the tremendous clinical impact that early intervention with therapeutic agents that selectively target the invasive and metastatic potential of the prostate cancer cell could have on patient survival and quality of life. Our research is currently focused on the development and testing of novel voltage-gated ion channel blockers. The expression of voltage-gated sodium channels (VGSCs) was recently associated with the metastatic behavior of prostate cancer cells. In these studies, VGSC blockers altered prostate cancer cell morphology and arrested prostate cancer cell migration. Clinically, one of the most widely used sodium channel blockers is phenytoin. We have used rational drug design based on the phenytoin binding site in a VGSC to make novel sodium channel blockers with enhanced activity and minimal acute toxicity. Our initial studies in vitro demonstrate enhanced binding of the compounds to the sodium channel and increased inhibition of prostate cancer cell growth in culture and in soft agarose compared with phenytoin. These derivatives are currently being tested for their antitumor activity in human prostate cancer xenografts.",
keywords = "Calcium ions, Invasive disease, Proliferation, Sodium channel blockade",
author = "Sikes, {Robert A.} and Walls, {Alison M.} and William Brennen and Anderson, {James D.} and Indrani Choudhury-Mukherjee and Schenck, {Hilary A.} and Brown, {Milton L.}",
year = "2003",
month = "12",
language = "English (US)",
volume = "2",
pages = "181--187",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Therapeutic Approaches Targeting Prostate Cancer Progression Using Novel Voltage-Gated Ion Channel Blockers

AU - Sikes, Robert A.

AU - Walls, Alison M.

AU - Brennen, William

AU - Anderson, James D.

AU - Choudhury-Mukherjee, Indrani

AU - Schenck, Hilary A.

AU - Brown, Milton L.

PY - 2003/12

Y1 - 2003/12

N2 - The early detection and treatment of prostate cancer have increased survival and improved clinical outcomes. The nature of the disease and pathologic understaging result in a high proportion of patients developing locally recurrent disease or distant metastases. The development of prostate cancer-the time from tumor initiation and progression to invasive carcinoma-often begins in men in the fourth or fifth decades of life and extends across decades. This prolonged window highlights the tremendous clinical impact that early intervention with therapeutic agents that selectively target the invasive and metastatic potential of the prostate cancer cell could have on patient survival and quality of life. Our research is currently focused on the development and testing of novel voltage-gated ion channel blockers. The expression of voltage-gated sodium channels (VGSCs) was recently associated with the metastatic behavior of prostate cancer cells. In these studies, VGSC blockers altered prostate cancer cell morphology and arrested prostate cancer cell migration. Clinically, one of the most widely used sodium channel blockers is phenytoin. We have used rational drug design based on the phenytoin binding site in a VGSC to make novel sodium channel blockers with enhanced activity and minimal acute toxicity. Our initial studies in vitro demonstrate enhanced binding of the compounds to the sodium channel and increased inhibition of prostate cancer cell growth in culture and in soft agarose compared with phenytoin. These derivatives are currently being tested for their antitumor activity in human prostate cancer xenografts.

AB - The early detection and treatment of prostate cancer have increased survival and improved clinical outcomes. The nature of the disease and pathologic understaging result in a high proportion of patients developing locally recurrent disease or distant metastases. The development of prostate cancer-the time from tumor initiation and progression to invasive carcinoma-often begins in men in the fourth or fifth decades of life and extends across decades. This prolonged window highlights the tremendous clinical impact that early intervention with therapeutic agents that selectively target the invasive and metastatic potential of the prostate cancer cell could have on patient survival and quality of life. Our research is currently focused on the development and testing of novel voltage-gated ion channel blockers. The expression of voltage-gated sodium channels (VGSCs) was recently associated with the metastatic behavior of prostate cancer cells. In these studies, VGSC blockers altered prostate cancer cell morphology and arrested prostate cancer cell migration. Clinically, one of the most widely used sodium channel blockers is phenytoin. We have used rational drug design based on the phenytoin binding site in a VGSC to make novel sodium channel blockers with enhanced activity and minimal acute toxicity. Our initial studies in vitro demonstrate enhanced binding of the compounds to the sodium channel and increased inhibition of prostate cancer cell growth in culture and in soft agarose compared with phenytoin. These derivatives are currently being tested for their antitumor activity in human prostate cancer xenografts.

KW - Calcium ions

KW - Invasive disease

KW - Proliferation

KW - Sodium channel blockade

UR - http://www.scopus.com/inward/record.url?scp=0346875862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346875862&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 181

EP - 187

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 3

ER -